(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 12.28%
-0.67% $ 4.45
@ $5.48
Wydano: 14 vas. 2024 @ 22:23
Zwrot: -18.72%
Poprzedni sygnał: vas. 14 - 19:19
Poprzedni sygnał:
Zwrot: 1.96 %
Live Chart Being Loaded With Signals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema...
Stats | |
---|---|
Dzisiejszy wolumen | 2.64M |
Średni wolumen | 3.26M |
Kapitalizacja rynkowa | 918.17M |
EPS | $0 ( 2024-05-01 ) |
Następna data zysków | ( $-0.230 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.77 |
ATR14 | $0.0110 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
75.18 |
Last 100 transactions |
Buy: 4 343 991 | Sell: 822 588 |
Wolumen Korelacja
BioCryst Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
NAKD | 0.945 |
SNGX | 0.941 |
GSMG | 0.94 |
MICS | 0.938 |
CSSEP | 0.932 |
TENX | 0.931 |
GRNA | 0.931 |
IRBT | 0.93 |
BCYC | 0.93 |
BHTG | 0.928 |
10 Najbardziej negatywne korelacje | |
---|---|
NCAC | -0.944 |
MLTX | -0.944 |
LMNR | -0.944 |
TETC | -0.941 |
PPYAU | -0.938 |
SJ | -0.935 |
INSE | -0.935 |
PLBC | -0.933 |
ALTR | -0.932 |
RCEL | -0.932 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioCryst Pharmaceuticals Korelacja - Waluta/Towar
BioCryst Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $331.41M |
Zysk brutto: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2023 |
Przychody: | $331.41M |
Zysk brutto: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2022 |
Przychody: | $270.83M |
Zysk brutto: | $264.23M (97.57 %) |
EPS: | $-1.330 |
FY | 2021 |
Przychody: | $157.17M |
Zysk brutto: | $149.91M (95.38 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej